Stem Cell Therapy for Heart Failure Gets a Gold-Standard Trial

July 19, 2017

(Scientific American) – A cadre of scientists and companies is now trying to prevent or reverse cardiac damage by infusing a cocktail of stem cells into weakened hearts. One company, Melbourne, Australia–based Mesoblast, is already in late-stage clinical trials, treating hundreds of chronic heart failure patients with stem cell precursors drawn from healthy donors’ hip bones. A randomized trial that includes a placebo group is scheduled to complete enrollment next year.